Dr. Gerecitano is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1275 York Ave
New York, NY 10021Phone+1 646-227-3813
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Pennsylvania Health SystemResidency, Internal Medicine, 2000 - 2003
New York University School of MedicineClass of 2000
Certifications & Licensure
NJ State Medical License 2006 - 2025
NY State Medical License 2003 - 2018
PA State Medical License 2001 - 2003
Clinical Trials
- Bortezomib in Treating Patients With Lymphoproliferative Disorders Start of enrollment: 2001 Jun 01
- Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2005 Dec 13
- Lenalidomide in Treating Patients With AIDS-Associated Kaposi's Sarcoma Start of enrollment: 2010 Aug 27
- Join now to see all
Publications & Presentations
PubMed
- 214 citationsA Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients With Advanced Solid Tumors and LymphomasJeffrey R. Infante, P. A. Cassier, John F. Gerecitano, Petronella O. Witteveen, Rashmi Chugh
Clinical Cancer Research. 2016-12-01 - 680 citationsRequirement for transcription factor IRF-1 in NO synthase induction in macrophages.Ryutaro Kamijo, Hisashi Harada, Toshifumi Matsuyama, Maarten C. Bosland, J. Gerecitano
Science. 1994-03-18 - 33 citationsPharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphomaRebecca Goldstein, Shao Ning Yang, Tony Taldone, Betty Y. Chang, John F. Gerecitano
The Journal of Clinical Investigation. 2015-12-01
Press Mentions
EZH2 Inhibitor Tested as Epigentic Option in NHL TypesOctober 26th, 2017- Two Late-Stage Trials Test Novel PI3K Inhibitor in Non-Hodgkin LymphomaJune 16th, 2017
LBA-2 Venetoclax plus Rituximab Is Superior to Bendamustine plus Rituximab in Patients with Relapsed/ Refractory Chronic Lymphocytic Leukemia - Results from Pre-Planned Interim Analysis of the Randomized Phase 3 Murano StudyDecember 2nd, 2017
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
